St John's Wort for Depression: The Clinical Evidence, Drug Interactions and What to Expect

St John's Wort (Hypericum perforatum) holds a unique position in evidence-based natural medicine: it is both the most-studied herbal product for depression and the one with the most clinically significant drug interactions. Understanding both sides of this picture is essential for anyone considering it.

The Evidence: 38 Trials, WFSBP Recommended Rating

The 2025 Frontiers in Pharmacology scoping review identified 38 clinical trials evaluating St John's Wort for depression — the largest evidence base of any single herbal product for a psychiatric condition. The results across these trials:

• Versus placebo: 16 positive trials versus 9 negative trials — a clear overall positive signal for depression symptom reduction
• Versus antidepressants (imipramine, fluoxetine, sertraline): Equivalent efficacy in 11 of 16 comparative studies; superior in 4; worse in 1
• Side effect profile: In comparison trials, fewer side effects than antidepressants in most studies — notably fewer sexual side effects, weight changes, and discontinuation symptoms

These results earned St John's Wort the highest "+++ Recommended" rating from the international WFSBP/CANMAT psychiatric guidelines for nutraceuticals — the only herbal product to achieve this for monotherapy depression treatment. The American College of Physicians review in Annals of Internal Medicine similarly found evidence supporting its efficacy for mild-to-moderate depression.

Active Compounds and Mechanism

St John's Wort contains multiple bioactive compounds — the relative contribution of each to antidepressant effect remains debated, but the primary candidates are:

• Hypericin: The red pigment historically thought responsible; inhibits monoamine oxidase (MAO) and may influence dopamine and serotonin reuptake
• Hyperforin: Now considered the primary antidepressant compound — inhibits reuptake of serotonin, dopamine, noradrenaline, GABA, and glutamate simultaneously through a novel sodium channel mechanism (distinct from SSRI mechanism). Most standardised extracts are now calibrated to hyperforin content (5–6%) rather than hypericin
• Amentoflavone: Inhibits both MAO-A and MAO-B, contributing to increased monoamine availability

The net mechanism is broader than SSRIs — affecting multiple neurotransmitter systems simultaneously. This may explain both its efficacy for depression and its superior side effect profile compared to selective agents.

What the Evidence Shows: Strengths and Limitations

Strengths:

• Consistent positive effects for mild-to-moderate depression — the most strongly evidenced natural intervention for this indication
• Equivalent to low-dose antidepressants in multiple comparative trials
• Better tolerated than SSRIs in head-to-head studies — particularly regarding sexual function, sleep, and GI effects
• Backed by international psychiatric guidelines (WFSBP/CANMAT)

Limitations:

• Evidence is strongest for mild-to-moderate depression — not established for severe depression
• Studies vary considerably in extract standardisation and dose — making comparison across trials difficult
• Must not be combined with prescription antidepressants (serious serotonin syndrome risk)
• Significant drug interactions (see below) limit its appropriate use population

Drug Interactions: The Critical Safety Issue

St John's Wort is a potent inducer of cytochrome P450 enzymes (particularly CYP3A4, CYP2C9) and P-glycoprotein — the liver's drug-metabolising system. This causes it to accelerate the breakdown of many medications, reducing their blood levels and effectiveness. Critical interactions include:

• Oral contraceptives: Reduces blood levels of both oestrogen and progestogen components — documented cases of unintended pregnancy. Anyone on hormonal contraception (pill, patch, ring) must not take St John's Wort
• Warfarin (and other anticoagulants): Reduces anticoagulant levels — risk of blood clot, stroke, or thrombosis in patients on warfarin
• HIV medications: Particularly protease inhibitors and NNRTIs — significantly reduces drug levels, risking treatment failure and drug resistance
• Transplant immunosuppressants: Cyclosporin levels drop dramatically — documented cases of transplant rejection
• SSRIs, SNRIs, MAOIs: Combination risks serotonin syndrome — potentially life-threatening excess serotonin
• Statins, some cancer chemotherapy, digoxin: Various interactions affecting drug efficacy

The FDA issued a public health advisory about St John's Wort interactions. Before taking it, anyone on any prescription medication must check with their pharmacist or GP about interaction risk.

What to Expect: Dose, Onset, and Duration

• Dose: 300mg three times daily (900mg/day total) of standardised extract (0.3% hypericin and/or 5–6% hyperforin) — the dose used in most positive clinical trials
• Onset: 2–4 weeks for initial effects; 6–8 weeks for full therapeutic benefit — similar timeline to pharmaceutical antidepressants
• Duration: Most trials ran 4–12 weeks. For sustained benefit, treatment periods of 3–6 months are used clinically, followed by gradual tapering
• Photosensitivity: St John's Wort increases skin sensitivity to sunlight — particularly hypericin at high doses. Fair-skinned individuals should use sun protection during treatment
• Standardisation matters: Use extracts standardised to hyperforin (5–6%) and/or hypericin (0.3%) — generic unlicensed products with unknown active compound content may not replicate clinical trial results